A fluorine scan of non-peptidic inhibitors of neprilysin: Fluorophobic and fluorophilic regions in an enzyme active site
暂无分享,去创建一个
F. Diederich | M. Kansy | M. Morgenthaler | Björn Wagner | J. Aebi | F. Grüninger | D. Mona | Daniel Mona
[1] G. Klebe,et al. Potent inhibitors of tRNA-guanine transglycosylase, an enzyme linked to the pathogenicity of the Shigella bacterium: charge-assisted hydrogen bonding. , 2007, Angewandte Chemie.
[2] F. Diederich,et al. Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.
[3] Manfred Kansy,et al. Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities , 2007, ChemMedChem.
[4] F. Diederich,et al. Nonphosphate Inhibitors of IspE Protein, a Kinase in the Non‐Mevalonate Pathway for Isoprenoid Biosynthesis and a Potential Target for Antimalarial Therapy , 2007, ChemMedChem.
[5] F. Diederich,et al. Structure‐Based Design and Synthesis of the First Weak Non‐Phosphate Inhibitors for IspF, an Enzyme in the Non‐Mevalonate Pathway of Isoprenoid Biosynthesis , 2007 .
[6] F. Diederich,et al. A Novel Synthesis of Highly Substituted Perhydropyrrolizines, Perhydroindolizines, and Pyrrolidines: Inhibition of the Peptidyl‐Prolyl cis/trans Isomerase (PPIase) Pin1 , 2007 .
[7] F. Diederich,et al. Mapping the Fluorophilicity of a Hydrophobic Pocket: Synthesis and Biological Evaluation of Tricyclic Thrombin Inhibitors Directing Fluorinated Alkyl Groups into the P Pocket , 2006, ChemMedChem.
[8] Manfred Kansy,et al. A Fluorine Scan at the Catalytic Center of Thrombin: CF, COH, and COMe Bioisosterism and Fluorine Effects on pKa and log D Values , 2006, ChemMedChem.
[9] F. Diederich,et al. Second-Generation Inhibitors for the Metalloprotease Neprilysin Based on Bicyclic Heteroaromatic Scaffolds: Synthesis, Biological Activity, and X-ray Crystal Structure Analysis , 2005 .
[10] F. Diederich,et al. A New Class of Inhibitors for the Metalloprotease Neprilysin Based on a Central Imidazole Scaffold , 2005 .
[11] W. R. Dolbier,et al. Fluorine chemistry at the millennium , 2005 .
[12] F. Diederich,et al. Structure‐Based Design, Synthesis, and in vitro Evaluation of Nonpeptidic Neprilysin Inhibitors , 2004, Chembiochem : a European journal of chemical biology.
[13] C. Urch,et al. Experimental Measurement of Noncovalent Interactions Between Halogens and Aromatic Rings , 2004, Chembiochem : a European journal of chemical biology.
[14] Martin Stahl,et al. Fluorine in Medicinal Chemistry , 2004, Chembiochem : a European journal of chemical biology.
[15] F. Diederich,et al. A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions. , 2004, Organic & biomolecular chemistry.
[16] E. Kool,et al. Selective pairing of polyfluorinated DNA bases. , 2004, Journal of the American Chemical Society.
[17] B. Roques,et al. Structural analysis of neprilysin with various specific and potent inhibitors. , 2004, Acta crystallographica. Section D, Biological crystallography.
[18] Paul Seiler,et al. A fluorine scan of thrombin inhibitors to map the fluorophilicity/fluorophobicity of an enzyme active site: evidence for C-F...C=O interactions. , 2003, Angewandte Chemie.
[19] F. Diederich,et al. Interactions with aromatic rings in chemical and biological recognition. , 2003, Angewandte Chemie.
[20] P. Coric,et al. Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP). , 2002, Journal of medicinal chemistry.
[21] Bruce E. Smart,et al. Fluorine substituent effects (on bioactivity) , 2001 .
[22] T. Saido,et al. Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.
[23] J. Schwartz,et al. Vasopeptidase inhibitors: an emerging class of cardiovascular drugs. , 2001, Trends in pharmacological sciences.
[24] D. Coates,et al. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.
[25] Chu-Young Kim,et al. Contribution of Fluorine to Protein−Ligand Affinity in the Binding of Fluoroaromatic Inhibitors to Carbonic Anhydrase II , 2000 .
[26] T. Saido,et al. Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.
[27] F. Winkler,et al. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. , 2000, Journal of molecular biology.
[28] T. Saido,et al. Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.
[29] Christopher A. Hunter,et al. Hydrogen-bond recognition of cyclic dipeptides in water , 1998 .
[30] A. Jeng,et al. Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11 , 1997 .
[31] K. Tanzawa,et al. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] Robin Taylor,et al. Organic Fluorine Hardly Ever Accepts Hydrogen Bonds , 1997 .
[33] Some influences of fluorine in bioorganic chemistry , 1997 .
[34] Regine Bohacek,et al. Three-Dimensional Models of ACE and NEP Inhibitors and Their Use in the Design of Potent Dual ACE/NEP Inhibitors , 1996 .
[35] M. Fournié-Zaluski,et al. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. , 1996, Journal of medicinal chemistry.
[36] L. Juliano,et al. A highly selective assay for neutral endopeptidase based on the cleavage of a fluorogenic substrate related to Leu-enkephalin. , 1996, Analytical biochemistry.
[37] Paul R. Gerber,et al. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..
[38] M. Fournié-Zaluski,et al. Inhibitors of neprilysin: design, pharmacological and clinical applications. , 1995, Methods in enzymology.
[39] M. Fournié-Zaluski,et al. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. , 1993, Pharmacological reviews.
[40] H. Stein,et al. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Skidgel,et al. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones 1 , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] A. Kenny,et al. Role of endopeptidase‐24.11 in the inactivation of atrial natriuretic peptide , 1988, FEBS letters.
[43] Davidr . Evans,et al. Asymmetric synthesis of the enkephalinase inhibitor thiorphan , 1985 .
[44] A. Turner,et al. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Schwartz,et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice , 1980, Nature.
[46] J. Schwartz,et al. High-affinity enkephalin-degrading peptidase in brain is increased after morphine , 1978, Nature.
[47] L. Stein,et al. Analgesia induced in vivo by central administration of enkephalin in rat , 1976, Nature.
[48] M. Kerr,et al. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. , 1974, The Biochemical journal.